{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:41:42Z","timestamp":1777588902033,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81573504"],"award-info":[{"award-number":["No. 81573504"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81673509"],"award-info":[{"award-number":["No. 81673509"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7171012"],"award-info":[{"award-number":["7171012"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Major Projects for \"Major New Drugs Innovation and Development\" of China","award":["2017ZX09101001"],"award-info":[{"award-number":["2017ZX09101001"]}]},{"name":"National Science and Technology Major Projects for \"Major New Drugs Innovation and Development\" of China","award":["2017ZX09304028"],"award-info":[{"award-number":["2017ZX09304028"]}]},{"name":"National Key R&D Program of China","award":["2016YFC0904900"],"award-info":[{"award-number":["2016YFC0904900"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1111\/jcpt.12780","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T05:59:07Z","timestamp":1545199147000},"page":"163-173","source":"Crossref","is-referenced-by-count":32,"title":["Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis"],"prefix":"10.1155","volume":"44","author":[{"given":"Xiaodan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy; Base for Clinical Trial, Peking University First Hospital; Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Base for Clinical Trial, Peking University First Hospital; Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Base for Clinical Trial, Peking University First Hospital; Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyue","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Base for Clinical Trial, Peking University First Hospital; Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Base for Clinical Trial, Peking University First Hospital; Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"10.1111\/jcpt.12780-BIB0001|jcpt12780-cit-0001","first-page":"1","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2016"},{"key":"10.1111\/jcpt.12780-BIB0002|jcpt12780-cit-0002","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jad.2017.12.021","article-title":"Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice","volume":"1","author":"Cuomo","year":"2018","journal-title":"J Affect Disord"},{"key":"10.1111\/jcpt.12780-BIB0003|jcpt12780-cit-0003","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1038\/npp.2014.65","article-title":"Identification of candidate single-nucleotide polymorphisms in nrxn1 related to antipsychotic treatment response in patients with schizophrenia","volume":"39","author":"Jenkins","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/jcpt.12780-BIB0004|jcpt12780-cit-0004","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.euroneuro.2008.07.010","article-title":"Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole","volume":"18","author":"Kwon","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/jcpt.12780-BIB0005|jcpt12780-cit-0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e31823f87ac","article-title":"Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and serum monoamine metabolites level during the acute phase of schizophrenia","volume":"32","author":"Miura","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/jcpt.12780-BIB0006|jcpt12780-cit-0006","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hup.2270","article-title":"Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China","volume":"27","author":"Zhang","year":"2012","journal-title":"Hum Psychopharmacol"},{"key":"10.1111\/jcpt.12780-BIB0007|jcpt12780-cit-0007","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1345\/aph.1C297","article-title":"Aripiprazole: A new atypical antipsychotic drug","volume":"37","author":"Bowles","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jcpt.12780-BIB0008|jcpt12780-cit-0008","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","article-title":"Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability","volume":"26","author":"Deleon","year":"2004","journal-title":"Clin Ther"},{"key":"10.1111\/jcpt.12780-BIB0009|jcpt12780-cit-0009","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet Med"},{"key":"10.1111\/jcpt.12780-BIB0010|jcpt12780-cit-0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1111\/jcpt.12780-BIB0011|jcpt12780-cit-0011","unstructured":"Food and Drug Administration Aripiprazole label 2017 https:\/\/www.pharmgkb.org\/chemical\/PA10026\/label\/PA166104839"},{"key":"10.1111\/jcpt.12780-BIB0012|jcpt12780-cit-0012","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-007-0373-6","article-title":"Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole","volume":"63","author":"Hendset","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12780-BIB0013|jcpt12780-cit-0013","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/1389200215666140202215316","article-title":"Challenges in CYP2D6 phenotype assignment from genotype data: A critical assessment and call for standardization","volume":"15","author":"Hicks","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1111\/jcpt.12780-BIB0014|jcpt12780-cit-0014","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.clpt.2005.08.013","article-title":"Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests","volume":"78","author":"Andersson","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12780-BIB0015|jcpt12780-cit-0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2133\/dmpk.18.48","article-title":"Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19","volume":"18","author":"Shimizu","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12780-BIB0016|jcpt12780-cit-0016","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2133\/dmpk.18.71","article-title":"Bioinformatics research on inter-racial difference in drug metabolism II. Analysis on relationship between enzyme activities of CYP2D6 and CYP2C19 and their relevant genotypes","volume":"18","author":"Shimizu","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12780-BIB0017|jcpt12780-cit-0017","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00008571-200405000-00002","article-title":"Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics","volume":"14","author":"Furman","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1111\/jcpt.12780-BIB0018|jcpt12780-cit-0018","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/FTD.0000000000000018","article-title":"Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype","volume":"36","author":"Hendset","year":"2014","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jcpt.12780-BIB0019|jcpt12780-cit-0019","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00228-015-1965-1","article-title":"Genotype and co-medication dependent CYP2D6 metabolic activity: Effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol","volume":"72","author":"Lisbeth","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12780-BIB0020|jcpt12780-cit-0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/FTD.0b013e3182031021","article-title":"Effects of the CYP2D6*10 allele on the steady-state serum concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in japanese patients with schizophrenia","volume":"33","author":"Suzuki","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jcpt.12780-BIB0021|jcpt12780-cit-0021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JCP.0000000000000319","article-title":"The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients","volume":"35","author":"Van der Weide","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/jcpt.12780-BIB0022|jcpt12780-cit-0022","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1111\/jcpt.12780-BIB0023|jcpt12780-cit-0023","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.2174\/1381612823666170817122043","article-title":"Genetic variants of PEAR1 are associated with platelet function and antiplatelet drug efficacy: A systematic review and meta-analysis","volume":"23","author":"Xiang","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.1111\/jcpt.12780-BIB0024|jcpt12780-cit-0024","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-ottawa scale. Comparing reviewers' to authors' assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1111\/jcpt.12780-BIB0025|jcpt12780-cit-0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2018.03.016","article-title":"Long non coding rna xist as a prognostic cancer marker - A meta-analysis","author":"Zhou","year":"2018","journal-title":"Clin Chim Acta"},{"key":"10.1111\/jcpt.12780-BIB0026|jcpt12780-cit-0026","first-page":"7526","article-title":"Assessing the influence of a single study in the meta-analysis estimate","volume":"8","author":"Tobias","year":"1999","journal-title":"Stata Tech Bull"},{"key":"10.1111\/jcpt.12780-BIB0027|jcpt12780-cit-0027","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1111\/jcpt.12780-BIB0028|jcpt12780-cit-0028","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1111\/jcpt.12780-BIB0029|jcpt12780-cit-0029","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00228-011-1094-4","article-title":"The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: Effects of cyp enzyme inhibition by coadministration of paroxetine or fluvoxamine","volume":"68","author":"Azuma","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12780-BIB0030|jcpt12780-cit-0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.20.55","article-title":"Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole","volume":"20","author":"Kubo","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12780-BIB0031|jcpt12780-cit-0031","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2133\/dmpk.22.358","article-title":"Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult japanese volunteers: Influence of CYP2D6 polymorphism","volume":"22","author":"Kubo","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12780-BIB0032|jcpt12780-cit-0032","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/FTD.0000000000000070","article-title":"Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state serum concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in japanese patients with schizophrenia","volume":"36","author":"Suzuki","year":"2014","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jcpt.12780-BIB0033|jcpt12780-cit-0033","unstructured":"SNPedia, CYP2D6 https:\/\/www.snpedia.com\/index.php\/CYP2D6"},{"key":"10.1111\/jcpt.12780-BIB0034|jcpt12780-cit-0034","unstructured":"PharmGKB website for FDA drug label of aripiprazole https:\/\/www.pharmgkb.org\/chemical\/PA10026\/label\/PA166104839"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12780","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12780\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:02Z","timestamp":1671818642000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12780","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,18]]}}}